CN111655719A - 内源性t细胞受体的靶向置换 - Google Patents

内源性t细胞受体的靶向置换 Download PDF

Info

Publication number
CN111655719A
CN111655719A CN201880084419.6A CN201880084419A CN111655719A CN 111655719 A CN111655719 A CN 111655719A CN 201880084419 A CN201880084419 A CN 201880084419A CN 111655719 A CN111655719 A CN 111655719A
Authority
CN
China
Prior art keywords
tcr
cells
nucleic acid
cell
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880084419.6A
Other languages
English (en)
Chinese (zh)
Inventor
T·L·罗斯
E·士夫洛特
A·曼森
C·P·召司
A·力巴斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Priority to CN202410674648.0A priority Critical patent/CN118581047A/zh
Publication of CN111655719A publication Critical patent/CN111655719A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880084419.6A 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换 Pending CN111655719A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410674648.0A CN118581047A (zh) 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578153P 2017-10-27 2017-10-27
US62/578,153 2017-10-27
PCT/US2018/058026 WO2019084552A1 (en) 2017-10-27 2018-10-29 TARGETED REPLACEMENT OF ENDOGENIC T CELL RECEPTORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410674648.0A Division CN118581047A (zh) 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换

Publications (1)

Publication Number Publication Date
CN111655719A true CN111655719A (zh) 2020-09-11

Family

ID=66247037

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880084419.6A Pending CN111655719A (zh) 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换
CN202410674648.0A Pending CN118581047A (zh) 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410674648.0A Pending CN118581047A (zh) 2017-10-27 2018-10-29 内源性t细胞受体的靶向置换

Country Status (13)

Country Link
US (6) US11033584B2 (cg-RX-API-DMAC7.html)
EP (1) EP3700924A4 (cg-RX-API-DMAC7.html)
JP (3) JP7101419B2 (cg-RX-API-DMAC7.html)
KR (2) KR102770787B1 (cg-RX-API-DMAC7.html)
CN (2) CN111655719A (cg-RX-API-DMAC7.html)
AU (2) AU2018355587B2 (cg-RX-API-DMAC7.html)
CA (1) CA3080415A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091056A1 (cg-RX-API-DMAC7.html)
IL (2) IL274179B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004325A (cg-RX-API-DMAC7.html)
MY (1) MY201694A (cg-RX-API-DMAC7.html)
SG (1) SG11202003798TA (cg-RX-API-DMAC7.html)
WO (1) WO2019084552A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062831A (zh) * 2021-03-24 2023-11-14 基因泰克公司 T淋巴细胞中的高效tcr基因编辑

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) * 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
EP3703712A4 (en) 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES
KR20200138334A (ko) 2018-04-02 2020-12-09 팩트 파마, 인크. 펩티드-MHC comPACT
CN112585277A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
US20210207174A1 (en) * 2018-05-25 2021-07-08 The Regents Of The University Of California Genetic engineering of endogenous proteins
IL316576A (en) 2019-02-12 2024-12-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
AU2020325225A1 (en) * 2019-08-05 2022-03-24 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making
EP3808765A1 (en) * 2019-10-14 2021-04-21 ETH Zurich Cell line for tcr discovery and engineering and methods of use thereof
JPWO2021095847A1 (cg-RX-API-DMAC7.html) * 2019-11-14 2021-05-20
CA3157411A1 (en) * 2019-11-15 2021-05-20 Karin Jooss Antigen-binding proteins targeting shared neoantigens
BR112022018218A2 (pt) * 2020-03-13 2022-12-20 Univ California Composições e métodos para modificar um ácido nucleico alvo
WO2022047003A1 (en) * 2020-08-27 2022-03-03 Tmunity Therapeutics Inc. Vector-free process for manufacture of engineered immune cells
JP2023544161A (ja) * 2020-10-02 2023-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんの改善されたt細胞免疫療法のためのdna構築物
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CN119486759A (zh) * 2022-02-14 2025-02-18 加利福尼亚大学董事会 用于改善t细胞免疫疗法的dna构建体
CN119677842A (zh) * 2022-03-17 2025-03-21 科士华(南京)生物技术有限公司 人工合成肿瘤浸润淋巴细胞
CR20250095A (es) 2022-09-13 2025-09-01 Arsenal Biosciences Inc Células inmunitarias que coexpresan arnhc de tgfbr
JP2025532585A (ja) 2022-09-16 2025-10-01 アーセナル バイオサイエンシズ インコーポレイテッド 組み合わせ遺伝子摂動を有する免疫細胞
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
CN121127257A (zh) * 2023-02-03 2025-12-12 Affini-T治疗有限公司 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法
US20260232734A1 (en) 2023-02-27 2026-08-13 Adaptive Biotechnologies Corporation Therapeutic T-Cell Receptors Targeting KRAS G12D
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2025193663A2 (en) * 2024-03-11 2025-09-18 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
TW202544044A (zh) 2024-03-20 2025-11-16 美商亞森諾生物科學公司 靶向slc34a2及tmprss4之系統及其使用方法
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
WO2026055342A1 (en) 2024-09-04 2026-03-12 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2026136848A2 (en) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Cd70-targeted cars and engineered cells comprising same and related methods
WO2026151965A1 (en) 2025-01-10 2026-07-16 Arsenal Biosciences, Inc. Shrna targeting fas and tgfbrii genes

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110158957A1 (en) * 2009-11-10 2011-06-30 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US20140301990A1 (en) * 2013-03-21 2014-10-09 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2016044745A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CN105452483A (zh) * 2013-03-15 2016-03-30 适应生物技术公司 复杂基因集合中的独特标记的重排适应性免疫受体基因
US20160272999A1 (en) * 2013-05-29 2016-09-22 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2017062439A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
WO2017062451A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
WO2017106528A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2003531616A (ja) 2000-04-28 2003-10-28 サンガモ バイオサイエンシーズ, インコーポレイテッド 細胞性クロマチンに外因性分子を結合させるための方法
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
JP4070611B2 (ja) 2001-04-23 2008-04-02 アマクサ アーゲー 電気穿孔法用の緩衝溶液およびその使用を含む方法
DK2574662T3 (da) 2001-08-22 2021-09-20 Maxcyte Inc Fremgangsmåde til elektroporation af biologiske prøver
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
ITMI20030821A1 (it) 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
CN1836048A (zh) 2003-06-10 2006-09-20 图尔金株式会社 可转导的dna结合蛋白
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
DE502004009820D1 (de) 2004-03-15 2009-09-10 Lonza Cologne Ag Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
WO2005113820A2 (en) 2004-05-12 2005-12-01 Maxcyte, Inc. Methods and devices related to a regulated flow electroporation chamber
RU2006143560A (ru) 2004-06-12 2008-07-20 Диджитал Био Технолоджи Ко Устройство для электропорации с удлиненным полым элементом
ES2465467T3 (es) 2004-06-14 2014-06-05 Lonza Cologne Ag Procedimiento y disposición de circuito para el tratamiento de material biológico
WO2005123962A2 (en) 2004-06-14 2005-12-29 The University Of Texas At Austin Gene targeting in eukaryotic cells by group ii intron ribonucleoprotein particles
JP2008521437A (ja) 2004-11-30 2008-06-26 マックスサイト インコーポレーティッド コンピュータ化されたエレクトロポレーション
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP2325332B1 (en) 2005-08-26 2012-10-31 DuPont Nutrition Biosciences ApS Use of CRISPR associated genes (CAS)
JP2010500029A (ja) 2006-08-11 2010-01-07 ダウ アグロサイエンシィズ エルエルシー ジンクフィンガーヌクレアーゼ媒介相同組換え
JP5779090B2 (ja) 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
EP2310500B1 (en) 2008-07-18 2015-03-11 Maxcyte, Inc. Methods for optimizing electroporation
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010129023A2 (en) 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US8876458B2 (en) 2011-01-25 2014-11-04 United Technologies Corporation Blade outer air seal assembly and support
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
CN105121650A (zh) 2013-04-02 2015-12-02 拜尔作物科学公司 真核生物中的靶向基因组工程
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9951353B2 (en) 2013-11-15 2018-04-24 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Engineering neural stem cells using homologous recombination
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
JP2016539653A (ja) 2013-12-13 2016-12-22 セレクティス 微小藻類のゲノム操作のためのCas9ヌクレアーゼプラットフォーム
KR102415811B1 (ko) 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
SG11201608701QA (en) 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016036754A1 (en) 2014-09-02 2016-03-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
CN113930455A (zh) 2014-10-09 2022-01-14 生命技术公司 Crispr寡核苷酸和基因剪辑
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
EP3247328B1 (en) 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
US20190388469A1 (en) 2015-01-30 2019-12-26 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
US12129471B2 (en) 2015-02-23 2024-10-29 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of human genetic diseases including hemoglobinopathies
WO2016172359A2 (en) 2015-04-24 2016-10-27 The Regents Of The University Of California Systems for detecting, monitoring or treating diseases or conditions using engineered cells and methods for making and using them
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
US11555207B2 (en) 2015-06-17 2023-01-17 The Uab Research Foundation CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
EP3310932B1 (en) 2015-06-17 2023-08-30 The UAB Research Foundation Crispr/cas9 complex for genomic editing
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017035659A1 (en) 2015-09-01 2017-03-09 The Hospital For Sick Children Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
KR20180043800A (ko) * 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017070169A1 (en) 2015-10-19 2017-04-27 The Methodist Hospital Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
US20180312873A1 (en) 2015-10-20 2018-11-01 10X Genomics, Inc. Method and systems for high throughput single cell genetic manipulation
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
AU2016359629B2 (en) 2015-11-23 2023-03-09 Ranjan BATRA Tracking and manipulating cellular RNA via nuclear delivery of CRISPR/Cas9
EP3397760A2 (en) 2015-12-30 2018-11-07 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
US20190241910A1 (en) * 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
AU2017248259A1 (en) 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
KR102614675B1 (ko) * 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
WO2017189336A1 (en) 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
KR102370675B1 (ko) 2016-04-29 2022-03-04 바스프 플랜트 사이언스 컴퍼니 게엠베하 표적 핵산의 변형을 위한 개선된 방법
WO2017210334A1 (en) 2016-05-31 2017-12-07 Massachusetts Institute Of Technology Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
US11713458B2 (en) 2016-06-20 2023-08-01 Octapharma Ag Means and methods for modifying multiple alleles
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018039084A1 (en) 2016-08-20 2018-03-01 The Regents Of The University Of California High-throughput system and method for the temporary permeablization of cells
AU2017341736B2 (en) 2016-10-12 2022-09-08 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
AU2017362513A1 (en) 2016-11-18 2019-05-16 Christopher Bradley Massively multiplexed homologous template repair for whole-genome replacement
RU2019121801A (ru) 2016-12-14 2021-01-15 Лигандал, Инк. Композиции и способы для доставки полезной нагрузки в виде нуклеиновой кислоты и/или белка
CN110546495B (zh) 2016-12-30 2022-11-01 加利福尼亚州立大学董事会 用于基因组编辑t细胞的选择和传代的方法
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) * 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
EP3703712A4 (en) 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110158957A1 (en) * 2009-11-10 2011-06-30 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN105452483A (zh) * 2013-03-15 2016-03-30 适应生物技术公司 复杂基因集合中的独特标记的重排适应性免疫受体基因
US20140301990A1 (en) * 2013-03-21 2014-10-09 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
US20160272999A1 (en) * 2013-05-29 2016-09-22 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2016044745A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
WO2017062439A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
WO2017062451A1 (en) * 2015-10-05 2017-04-13 Precision Biosciences, Inc. Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
WO2017106528A2 (en) * 2015-12-18 2017-06-22 Sangamo Biosciences, Inc. Targeted disruption of the t cell receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JUSTIN EYQUEM等: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection", 《NATURE》 *
JUSTIN EYQUEM等: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection", 《NATURE》, vol. 543, 2 March 2017 (2017-03-02), pages 113 *
KENDRA C. FOLEY等: "HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer", 《MOLECULAR THERAPY: ONCOLYTICS》 *
KENDRA C. FOLEY等: "HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer", 《MOLECULAR THERAPY: ONCOLYTICS》, vol. 5, 30 June 2017 (2017-06-30), pages 105 - 114 *
KENDRA C. FOLEY等: "HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer", MOLECULAR THERAPY: ONCOLYTICS, vol. 5, pages 105 - 114 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117062831A (zh) * 2021-03-24 2023-11-14 基因泰克公司 T淋巴细胞中的高效tcr基因编辑

Also Published As

Publication number Publication date
WO2019084552A1 (en) 2019-05-02
CN118581047A (zh) 2024-09-03
SG11202003798TA (en) 2020-05-28
US20200000851A1 (en) 2020-01-02
US20210228631A1 (en) 2021-07-29
EP3700924A1 (en) 2020-09-02
US11033584B2 (en) 2021-06-15
KR20230034416A (ko) 2023-03-09
JP7101419B2 (ja) 2022-07-15
BR112020008201A2 (pt) 2020-10-06
IL274179B1 (en) 2023-10-01
US11590171B2 (en) 2023-02-28
JP2024174943A (ja) 2024-12-17
EP3700924A4 (en) 2021-11-03
US20210353678A1 (en) 2021-11-18
US20220241336A1 (en) 2022-08-04
IL274179B2 (en) 2024-02-01
JP2022137112A (ja) 2022-09-21
AU2023202582B2 (en) 2026-01-08
US11083753B1 (en) 2021-08-10
KR20200088348A (ko) 2020-07-22
US20250361287A1 (en) 2025-11-27
JP2021500889A (ja) 2021-01-14
KR102503130B1 (ko) 2023-02-24
US11331346B2 (en) 2022-05-17
US20230310502A1 (en) 2023-10-05
AU2023202582A1 (en) 2023-05-18
IL305485B1 (en) 2025-06-01
AU2018355587A1 (en) 2020-06-18
MX2020004325A (es) 2020-11-09
AU2018355587B2 (en) 2023-02-02
IL305485B2 (en) 2025-10-01
EA202091056A1 (ru) 2020-09-17
MY201694A (en) 2024-03-13
CA3080415A1 (en) 2019-05-02
US12398193B2 (en) 2025-08-26
IL274179A (en) 2020-06-30
IL305485A (en) 2023-10-01
KR102770787B1 (ko) 2025-02-19

Similar Documents

Publication Publication Date Title
AU2023202582B2 (en) Targeted replacement of endogenous T cell receptors
JP7114117B2 (ja) 初代造血細胞におけるタンパク質送達
US20250369021A1 (en) Genetic engineering of endogenous proteins
CN112040986A (zh) 用于改进的免疫疗法的基因调控组合物和方法
CN111344020A (zh) 靶向非病毒dna插入
TW202235617A (zh) 用於減少細胞中ii類mhc之組合物及方法
CN106661570A (zh) 通过与氨甲蝶呤选择偶联的睡美人转座子制备工程化t细胞
JP2025529177A (ja) 低免疫原性を操作するための材料及び方法
EP4060038A1 (en) Method for introducing antigen-specific receptor gene into t cell genome using cyclic dna
HK40115874A (en) Targeted replacement of endogenous t cell receptors
HK40037128A (en) Targeted replacement of endogenous t cell receptors
EA050071B1 (ru) Направленная замена эндогенных т-клеточных рецепторов
BR112020008201B1 (pt) Método in vitro ou ex vivo para edição do genoma de uma célula t humana primária, composição, população de células t, e uso de uma célula t
JP2025532585A (ja) 組み合わせ遺伝子摂動を有する免疫細胞
CN116802274A (zh) 用于减少细胞中ii类mhc的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037128

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: Roth Tara Leigh

Inventor after: E. Sylvester

Inventor after: A. Manson

Inventor after: C. Pyg

Inventor after: Zhao Si

Inventor after: A. Libas

Inventor before: Roth Tara Leigh

Inventor before: E. Sylvester

Inventor before: A. Manson

Inventor before: C. P. Summoner

Inventor before: A. Libas

CB03 Change of inventor or designer information